Molecular Excipient

174.0 -1.3 5 3 125.0 5 0.67
Present in 112 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
NOS2 Nitric oxide synthase, inducible Enzyme / Enzyme-Other

Clinical Trials

This compound has been an intervention in the following clincial trials (per
Code Date Title Phase Status
NCT00345150 Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls Phase 1 Completed
NCT00344916 Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis Phase 1 Completed
NCT00005107 Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia Phase 1 Recruiting
NCT00345137 Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis Phase 1 Completed
NCT00344734 Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure Phase 1 Completed
NCT02388178 2015-04-01 To Determine the Ability of a New Product Formulation to Remineralize an Early Caries Lesion by an In-situ Study Phase 2 Not Yet Recruiting
NCT02291458 2014-11-01 L-arginine and Brown Adipose Tissue Phase 3 Recruiting
NCT01607879 2014-03-01 Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation Phase 2 Recruiting
NCT02017249 2014-03-01 Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme Phase 1 Recruiting
NCT01855334 2013-09-01 L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD Phase 4 Withdrawn
NCT01841281 2013-08-01 L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels Phase 2 Recruiting
NCT02245165 2013-06-01 Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades Phase 1 Completed
NCT01860911 2013-04-01 Plasma Triglyceride Extraction by The Muscle Phase 1 Recruiting
NCT01791816 2013-02-01 Mechanisms of Vasovagal Syncope Phase 0 Recruiting
NCT01710371 2012-12-01 Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls Phase 1 Recruiting
NCT01423799 2012-07-01 Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment Phase 3 Recruiting
NCT01603446 2012-05-01 L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome Phase 2 Completed
NCT01482247 2012-04-01 L-Arginine, Vascular Response and Mechanisms Phase 2 Completed
NCT01388764 2012-01-01 Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids Phase 1 Completed
NCT02009527 2012-01-01 Arginase Inhibition in Ischemia-reperfusion Injury Phase 1 Recruiting
NCT01439555 2011-11-01 Endothelial Facilitation in Alzheimer's Disease Phase 2 Recruiting
NCT01118520 2011-09-01 Evaluation of Effect of Angiotensin-converting Enzyme (ACE) Inhibitors on Small Aneurysm Growth Rate Phase 4 Recruiting
NCT01485757 2011-07-01 Prospective L-arginine Study Phase 1 Terminated
NCT01287585 2011-07-01 Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Phase 3 Active, Not Recruiting
NCT01263041 2011-05-01 Effect of L-arginine and Glutamine on Preterm Phase 2/Phase 3 Completed
NCT01324115 2011-04-01 NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors Phase 1 Terminated
NCT01266018 2010-12-01 Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer Phase 2 Active, Not Recruiting
NCT01105130 2010-10-01 L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors Phase 2 Completed
NCT02363348 2010-08-01 Efficacy and Safety of L Arginine to Prevent Preeclampsia Phase 3 Completed
NCT01070940 2010-02-01 L-NMMA Dose-response Study in Healthy Subjects Phase 1 Completed
NCT01052623 2010-01-01 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Phase 4 Recruiting
NCT01038622 2009-11-01 Directed Immuno Nutrition by L-arginine for Critically Ill Patients Phase 4 Completed
NCT00848302 2009-09-01 Endothelial Function in Human Arteries Phase 1 Completed
NCT00856817 2009-03-01 Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation Phase 4 Terminated
NCT00995839 2008-11-01 Terlipressin in Septic Shock: Effects on Microcirculation Phase 2/Phase 3 Completed
NCT00785811 2008-10-01 Effect of Chronic Supplementation of L-arginine in the Muscular Performance Phase 4 Terminated
NCT00917826 2008-09-01 Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies Phase 2 Terminated
NCT00677339 2008-06-01 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) Phase 3 Completed
NCT00616304 2008-02-01 Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria Phase 2 Suspended
NCT00345605 2008-02-01 Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder Phase 2 Completed
NCT00406731 2008-01-01 Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure Phase 2 Withdrawn
NCT00571766 2007-11-01 Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy Phase 3 Completed
NCT00974714 2007-09-01 L-arginine Effects on Chronic Hypertension in Pregnancy Phase 3 Completed
NCT00490100 2007-06-01 Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Phase 1/Phase 2 Completed
NCT01682889 2007-01-01 The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation Phase 4 Completed
NCT00753948 2006-12-01 Exhaled Levels of Nitric Oxide Phase 2/Phase 3 Completed
NCT00405665 2006-11-01 The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis Phase 2 Completed
NCT01142219 2006-09-01 L-Arginine and Sickle Cell Disease Phase 3 Completed
NCT01742702 2006-06-01 Haemodynamics in Hypertension Phase 0 Recruiting
NCT00137124 2006-05-01 L-Arginine Metabolism in Essential Hypertension Phase 2/Phase 3 Completed
NCT00200746 2006-04-01 Treatment of Alcohol-Related Hepatitis With Arginine Phase 2 Withdrawn
NCT00917449 2005-12-01 Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome Phase 3 Completed
NCT02117206 2005-11-01 Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans Phase 4 Completed
NCT00708357 2005-05-01 Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head? Phase 0 Terminated
NCT00264706 2005-03-01 PolyArginine Treated vEiN grafTs (PATENT) Phase 1/Phase 2 Active, Not Recruiting
NCT00147368 2005-02-01 Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria Phase 1/Phase 2 Completed
NCT00569465 2005-01-01 N-Acetylcysteine and Arginine Administration in Diabetic Patients Phase 4 Terminated
NCT00410085 2005-01-01 Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls Phase 4 Completed
NCT00280683 2004-12-01 Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma Phase 2 Completed
NCT00134433 2004-11-01 Endothelial Modulation for Angiogenic Therapy Phase 1/Phase 2 Completed
NCT00408577 2004-11-01 Prevention of Cardiac and Vascular Events in Patients With NGT/IGT. Phase 3 Completed
NCT00513617 2004-06-01 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Phase 2 Completed
NCT00127907 2004-05-01 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Phase 4 Completed
NCT00047983 2004-04-01 Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients Phase 0 Completed
NCT00213915 2004-02-01 L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function Phase 4 Completed
NCT01775020 2003-10-01 Dose-response Study of Arginine Supplementation in Severe Sepsis Phase 0 Completed
NCT00777075 2003-07-01 L-Arginine and Erectile Dysfunction Phase 4 Completed
NCT00902616 2003-06-01 Effect of Arginine on Microcirculation in Patients With Diabetes Phase 4 Completed
NCT00237770 2003-06-01 Prevention of Low Blood Pressure in Persons With Tetraplegia Phase 2/Phase 3 Completed
NCT00056433 2003-03-01 Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia Phase 1 Completed
NCT00157521 2002-09-01 L-Arginine in Pre-Eclampsia Phase 3 Completed
NCT00431392 2001-09-01 Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions Phase 2 Completed
NCT00029731 2001-08-01 Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients Phase 2 Completed
NCT00223717 2001-06-01 Treatment of Supine Hypertension in Autonomic Failure Phase 1/Phase 2 Recruiting
NCT00134420 2001-02-01 Growth Hormone and Chromosome 18q- and Abnormal Growth Phase 3 Active, Not Recruiting
NCT00469846 2001-01-01 L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia Phase 2 Terminated
NCT01796678 2000-09-01 Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial Phase 2 Completed
NCT00006136 1999-03-01 Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia Phase 2 Completed
NCT00001752 1998-09-01 Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women Phase 2 Completed
NCT00004412 1997-09-01 Phase II Randomized Trial of Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Phase 2 Recruiting
NCT00006340 1994-12-01 Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus Phase 1 Completed

(Browse) Purchasable Analogs in ZINC


Route Formulation Per Unit Dose
Im - Iv Injection
Im - Iv Powder, For Injection Solution
Im - Iv Powder, For Injection Solution, Lyophilized 15.6%W/V
Intravenous Injectable 5%
Intravenous Injection 39.5%
Intravenous Powder, For Injection Solution 15.6%W/V
Intravenous Solution, Injection
Iv(infusion) Injection 88%
Iv(infusion) Solution, Injection 0.29%
Oral Tablet 25MG

More Information

Usage Over Time